Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists

Clinical Therapeutics

Volumn 32, Issue 10, 2010, Pages 1749-1751

  Miller, Bradley S ^a   Shukla, Aseem R ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Histrelin; Leuprolide; Lupron Depot Ped; Precocious puberty; Sterile abscess; Supprelin LA

Indexed keywords

HISTRELIN; LEUPRORELIN; LONG ACTING DRUG; NAFARELIN;

ARTICLE; CASE REPORT; CENTRAL PRECOCIOUS PUBERTY; CHILD; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE ABSCESS; PUBERTY DISORDERS; SCHOOL CHILD; WOUND DRAINAGE;

ABSCESS; CHILD; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUPROLIDE; NAFARELIN; PUBERTY, PRECOCIOUS; RECEPTORS, LHRH;

EID: 78650623299     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.09.009     Document Type: Article

References (16)

1. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009, 123:e752-e762. ESPE-LWPES GnRH Analogs Consensus Conference Group.
2. Lupron Depot Ped (leuprolide acetate for depot suspension) [package insert] 2008, Abbott Laboratories, North Chicago, Ill, Accessed January 23, 2010. http://www.rxabbott.com/pdf/lupronpediatric.pdf.
3. Carel JC, Lahlou N, Jaramillo O, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab. 2002, 87:4111-4116.
4. Manasco PK, Pescovitz OH, Blizzard RM Local reactions to depot leuprolide therapy for central precocious puberty. J Pediatr. 1993, 123:334-335.
5. Neely EK, Hintz RL, Parker B, et al. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr. 1992, 121:634-640.
6. Tonini G, Marinoni S, Forleo V, Rustico M Local reactions to luteinizing hormone releasing hormone analog therapy. J Pediatr. 1995, 126:159-160.
7. Supprelin LA (histrelin implant) [package insert] 2009, Endo Pharmaceuticals Solutions Inc, Chadds Ford, Pa, Accessed January 23, 2010. http://www.supprelinla.com/endocrinologists/images/pdf/prescribinginformation.pdf.
8. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: A multicenter trial. J Clin Endocrinol Metab. 2007, 92:1697-1704.
9. Rahhal S, Clarke WL, Kletter GB, et al. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol. 2009, 2009:812517.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-245.
11. Daskivich TJ, Oh WK Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: Insight into mechanisms?. Urology 2006, 67:1084.
12. Daskivich TJ, Oh WK Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: Insight into mechanisms?. Urology 2006, 67:e15-e17.
13. Curry EA, Sweeney CJ Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. J Urol. 2002, 168:193.
14. Vantas (histrelin implant) [package insert]. Endo Pharmaceuticals, Cranbury, NJ Accessed January 23, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21732lbl.pdf.
15. Schlegel PN Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol. 2006, 175:1353-1358. Histrelin Study Group.
16. Schlegel PN, Kuzma P, Frick J, et al. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology. 2001, 58:578-582.